Z Gastroenterol 2015; 53(11): 1350-1352
DOI: 10.1055/s-0041-103525
Aktuelle Studien
© Georg Thieme Verlag KG Stuttgart · New York

Die INCA-Studie (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): Präzise medizinische Therapie der Patienten mit Leberzirrhose und Aszites

The INCA trial (impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): Precision medicine for patients with liver cirrhosis and ascites
M. Casper
,
B. Appenrodt
,
F. Grünhage
,
F. Lammert
Further Information

Publication History

23 June 2015

06 July 2015

Publication Date:
12 November 2015 (online)

 
  • Literatur

  • 1 Appenrodt B, Grünhage F, Gentemann MG et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-1333
  • 2 Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: From pathophysiology to clinical practice. J Hepatol 2015; 62: S6-S14
  • 3 Jameson JL, Longo DL. Precision medicine – personalized, problematic and promising. N Engl J Med 2015; 372: 229-2234